Literature DB >> 9016887

Atherosclerotic ischemic renal disease.

B A Greco1, J A Breyer.   

Abstract

Over the past decade, ischemic nephropathy has gained recognition as a distinct and treatable clinical entity. Atherosclerotic renal artery stenosis is the leading cause of ischemic renal disease. Among the aging population entering renal replacement programs, both renal artery and systemic atherosclerosis are common. Over recent years, patients with ischemic renal disease are presenting later and have diffuse atherosclerosis and other comorbid conditions. Improved screening techniques, patient selection, and interventional approaches have resulted in better outcomes in most centers. Percutaneous transluminal renal angioplasty has emerged as the treatment of choice in some centers for nonostial renal artery stenosis. Both percutaneous transluminal renal angioplasty and surgical repair have proven beneficial for renal function salvage. Many studies have elegantly demonstrated the pathophysiologic consequences of acute ischemia to the kidney. The concepts derived from acute studies have served as a springboard for considering the adaptive and maladaptive renal responses to chronic ischemia.

Entities:  

Mesh:

Year:  1997        PMID: 9016887     DOI: 10.1016/s0272-6386(97)90027-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

Review 1.  Renal failure in atherosclerotic renovascular disease: pathogenesis, diagnosis, and intervention.

Authors:  R G Woolfson
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

2.  MicroRNA profiling in kidney disease: Plasma versus plasma-derived exosomes.

Authors:  Jeffrey X Xie; Xiaoming Fan; Christopher A Drummond; Reetam Majumder; Yanmei Xie; Tian Chen; Lijun Liu; Steven T Haller; Pamela S Brewster; Lance D Dworkin; Christopher J Cooper; Jiang Tian
Journal:  Gene       Date:  2017-06-03       Impact factor: 3.688

3.  Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease.

Authors:  Alfons Segarra-Medrano; Marisa Martin; Irene Agraz; Mercè Vilaprinyó; Betty Chamoun; Elias Jatem; Maria Molina; Laura Colàs-Campàs; Alicia Garcia-Carrasco; Sarai Roche
Journal:  Clin Kidney J       Date:  2019-08-01

Review 4.  Cardiorenal syndrome: pathophysiology and potential targets for clinical management.

Authors:  Parta Hatamizadeh; Gregg C Fonarow; Matthew J Budoff; Sirous Darabian; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

Review 5.  Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond.

Authors:  Lilach O Lerman; Stephen C Textor; Joseph P Grande
Journal:  Prog Cardiovasc Dis       Date:  2009 Nov-Dec       Impact factor: 8.194

Review 6.  Endovascular versus medical therapy for atherosclerotic renovascular disease.

Authors:  Mark Shipeng Yu; David A Folt; Christopher A Drummond; Steven T Haller; Emily L Cooper; Pamela Brewster; Kaleigh L Evans; Christopher J Cooper
Journal:  Curr Atheroscler Rep       Date:  2014-12       Impact factor: 5.113

7.  Atherosclerotic ischemic renal disease. Diagnosis and prevalence in an hypertensive and/or uremic elderly population.

Authors:  Giorgio Coen; Santo Calabria; Silvia Lai; Eleonora Moscaritolo; Italo Nofroni; Giuseppe Ronga; Michele Rossi; Guido Ventroni; Daniela Sardella; Michele Ferrannini; Alvaro Zaccaria; Rosario Cianci
Journal:  BMC Nephrol       Date:  2003-02-06       Impact factor: 2.388

8.  Relationship between Renal Artery Stenosis and Severity of Coronary Artery Disease in Patients with Coronary Atherosclerotic Disease.

Authors:  Amirfarhang Zandparsa; Mehrdad Habashizadeh; Ehsan Moradi Farsani; Mostafa Jabbari; Razieh Rezaei
Journal:  Int Cardiovasc Res J       Date:  2012-09-15

Review 9.  The diagnosis and management of renovascular disease: a primary care perspective. Part I. Making the diagnosis.

Authors:  Michael J Bloch; Jan Basile
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

Review 10.  Cell-based regenerative medicine for renovascular disease.

Authors:  Lilach O Lerman
Journal:  Trends Mol Med       Date:  2021-06-25       Impact factor: 15.272

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.